In reply to @douglasyaody

My new drug PAC-3310 improves on Cobenfry by exhibiting a much better selectivity profile across the five muscarinic receptors. In functional cell assays, PAC-3310 has nanomolar potency for M4 (EC50 = 97 nM) and >100x selectivity over M1, M2, M3, and M5 (EC50 > 10 uM for each).